- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRISALUS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 12.10. | Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call | 1 | Benzinga.com | ||
| 23.09. | TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support | 6 | Benzinga.com | ||
| 23.09. | TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday | 1 | Benzinga.com | ||
| 23.09. | H.C. Wainwright raises TriSalus stock price target on FDA approval | 3 | Investing.com | ||
| 23.09. | TriSalus jumps 16% after FDA clears TriNav Advance device | 1 | Seeking Alpha | ||
| 22.09. | TriSalus Life Sciences: Aktie steigt nach FDA-Zulassung um 29 % | 2 | Investing.com Deutsch | ||
| 22.09. | TriSalus erhält FDA-Zulassung für das System TriNav Advance | 2 | Investing.com Deutsch | ||
| 22.09. | TriSalus receives FDA clearance for TriNav Advance device | 2 | Investing.com | ||
| 22.09. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | TriSalus Life Sciences GAAP EPS of -$0.16 misses by $0.01, revenue of $11.41M beats by $1.14M | 2 | Seeking Alpha | ||
| 07.08. | Trisalus reiterates 2026 revenue guidance of $54M-$57M as CMS G-code expands TriNav reimbursement into office-based labs | 1 | Seeking Alpha | ||
| 06.08. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Canaccord reiterates TriSalus stock Buy rating after KOL event | 1 | Investing.com | ||
| 18.05. | TriSalus Life Sciences: Aktie steigt trotz Umsatzrückgang im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 13.05. | TriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goal | 1 | Seeking Alpha | ||
| 12.05. | TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 12.05. | TriSalus Life Sciences GAAP EPS of $0.03 beats by $0.19, revenue of $8.9M misses by $1.54M | 2 | Seeking Alpha | ||
| 12.05. | TriSalus senkt Umsatzprognose für 2026 auf 54-57 Mio. US-Dollar | 3 | Investing.com Deutsch | ||
| 12.05. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 16,886 | +1,20 % | Viatris Inc.: Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. | PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary... ► Artikel lesen | |
| SYNBIOTIC | 0,158 | -4,12 % | SYNBIOTIC SE: Zuvor aufgezeigte Risiken haben sich materialisiert; Rating und Kursziel under review | SYNBIOTIC hat angekündigt, einen Insolvenzantrag zu stellen, nachdem es dem Unternehmen angesichts anhaltend schwieriger Marktbedingungen nicht gelungen ist, eine ausreichende Finanzierung sicherzustellen.... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,816 | -5,45 % | Organigram Global Inc. to Acquire Aurora Cannabis Inc. and Establish a Global Cannabis Leader | • Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 4,618 | +0,65 % | Tonix Pharmaceuticals ernennt George Lederman zum Executive Vice President | ||
| ORAMED PHARMACEUTICALS | 3,505 | -1,96 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 7,920 | +3,66 % | Sellas Life Sciences Group rutscht nach neuen Daten ab: Warum der Markt nervös bleibt | ||
| OPKO HEALTH | 1,580 | +2,60 % | OPKO Health, Inc.: OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026 | ||
| XORTX THERAPEUTICS | 0,803 | +0,50 % | XORTX Therapeutics Inc.: XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity | CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative... ► Artikel lesen | |
| SOLIGENIX | 0,356 | +0,03 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| OPUS GENETICS | 3,220 | -3,01 % | Opus Genetics, Inc.: Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| TALPHERA | 0,885 | -3,28 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,232 | +0,24 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| SCYNEXIS | 3,505 | +2,19 % | SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | • SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated • Phase 2 proof-of-concept study in patients with ADPKD remains... ► Artikel lesen | |
| PROTHENA | 7,590 | +2,35 % | Prothena Corporation plc: Prothena to Report Third Quarter 2026 Financial Results on November 5 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 3,205 | +1,75 % | Wave Life Sciences, Inc. - 10-Q, Quarterly Report |
TRISALUS LIFE SCIENCES INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,57 % bei einem Aktienkurs von 3,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRISALUS LIFE SCIENCES INC finden Sie auf Wallstreet Online.